Lixte Forum: Community User: DeRitter

Kommentare 147
DeRitter
DeRitter, 04.05.2021 17:15 Uhr
0
In dem Markt? Eine der wenigen grünen Positionen heute
Tennis123
Tennis123, 04.05.2021 14:03 Uhr
0
Könnte mal steigen
DeRitter
DeRitter, 29.04.2021 9:17 Uhr
0
Willkommen im Klub 🤞🏻
Tennis123
Tennis123, 29.04.2021 9:10 Uhr
0
Mal sehen ob was kommt bezüglich Krebs
Tennis123
Tennis123, 29.04.2021 9:10 Uhr
1
Auch drin
van_haze78
van_haze78, 28.04.2021 22:36 Uhr
0
Schauen wir wo die Reise hingeht 💪
DeRitter
DeRitter, 28.04.2021 21:52 Uhr
0
Wir heben ab
DeRitter
DeRitter, 17.03.2021 14:54 Uhr
1
LIXT PR "EAST SETAUKET, NY, March 17, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, will participate in the virtual Benzinga Biotech Small Cap Conference being held March 24-25, 2021. Lixte Founder and Chief Executive Officer John S. Kovach, M.D., will present on Wednesday, March 24 at 10:55 a.m. ET in Track 1. Investors may register for the conference at the event website. During the corporate presentation and in one-on-one investor meetings, Dr. Kovach will discuss Lixte's product pipeline of ongoing studies and planned trials of its lead clinical candidate LB-100, a unique first-in-class anti-cancer agent with no competitors known to Lixte currently in the clinic. Dr. Kovach commented, "More than 40 preclinical studies with leading medical centers indicated that LB-100 enhances standard therapies for many cancers. We now have a number of exciting clinical investigations underway for LB-100, including three clinical trials and one pharmacology study. Our initial cancer targets are myelodysplastic syndrome, soft tissue sarcomas, small cell lung cancer, and glioblastoma.""
TheOneDay
TheOneDay, 15.03.2021 12:47 Uhr
0
Pump and Dump 😂👍
DeRitter
DeRitter, 15.03.2021 9:03 Uhr
0
👍👍
MS85
MS85, 13.03.2021 16:19 Uhr
0
🤗
DeRitter
DeRitter, 12.03.2021 23:36 Uhr
0
To be presented - Anti-Cancer Therapy Enhancer LB-100 at the Virtual 33rd Annual ROTH Capital Conference LB-100 is Currently in Clinical Studies for Four Cancer Targets: ◦ Phase 1b/2 for Myelodysplastic (MDS) Syndromes ◦ Phase 1b/2 for Advanced Soft Tissue Sarcoma ◦ Phase 0 (Pharmacodynamics) for Glioblastoma Multiforme ◦ Phase 1b for Small Cell Lung Cancer ◦ Pre-clinical for Angelman Syndrome
WALL.E
WALL.E, 12.03.2021 22:15 Uhr
0
👋
D
Drexxtor, 12.03.2021 22:04 Uhr
0
🧐🧐🧐
DeRitter
DeRitter, 12.03.2021 22:04 Uhr
0
🐥🐥🐥
WALL.E
WALL.E, 12.03.2021 22:01 Uhr
0
😉
Meistdiskutiert
Thema
1 Gorilla -2,30 %
2 Micron Neu +3,53 %
3 Lithium -10,00 %
4 RIM - RESEARCH IN MOTION Hauptdiskussion +1,83 %
5 Phunware 2025 +1,44 %
6 OCCIDENTAL PETROLEUM Hauptdiskussion -2,97 %
7 Atyr Pharma +10,03 %
8 TUI Hauptforum +1,28 %
9 ADIDAS Hauptdiskussion -1,06 %
10 Super Micro Computer Hauptdiskussion +10,20 %
Alle Diskussionen
Aktien
Thema
1 Gorilla -2,30 %
2 Micron Neu +3,53 %
3 Lithium -10,00 %
4 RIM - RESEARCH IN MOTION Hauptdiskussion +1,83 %
5 Phunware 2025 +1,44 %
6 OCCIDENTAL PETROLEUM Hauptdiskussion -2,97 %
7 Atyr Pharma +10,03 %
8 TUI Hauptforum +1,28 %
9 ADIDAS Hauptdiskussion -1,06 %
10 Super Micro Computer Hauptdiskussion +10,20 %
Alle Diskussionen